Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,8625682,HR,"While HR did not change in the LOW group (90 +/- 4 to 93 +/- 3 beats/min), HR increased significantly in the HIGH group (94 +/- 5 to 112 +/- 8 beats/min) (baseline to 60 min infusion time points).",Pharmacodynamics and pharmacokinetics of milrinone administration to increase oxygen delivery in critically ill patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8625682/),[beats] / [min],90,237,DB01427,Amrinone
,8625682,HR,"While HR did not change in the LOW group (90 +/- 4 to 93 +/- 3 beats/min), HR increased significantly in the HIGH group (94 +/- 5 to 112 +/- 8 beats/min) (baseline to 60 min infusion time points).",Pharmacodynamics and pharmacokinetics of milrinone administration to increase oxygen delivery in critically ill patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8625682/),[beats] / [min],93,238,DB01427,Amrinone
,8625682,HR,"While HR did not change in the LOW group (90 +/- 4 to 93 +/- 3 beats/min), HR increased significantly in the HIGH group (94 +/- 5 to 112 +/- 8 beats/min) (baseline to 60 min infusion time points).",Pharmacodynamics and pharmacokinetics of milrinone administration to increase oxygen delivery in critically ill patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8625682/),[beats] / [min],94,239,DB01427,Amrinone
,8625682,HR,"While HR did not change in the LOW group (90 +/- 4 to 93 +/- 3 beats/min), HR increased significantly in the HIGH group (94 +/- 5 to 112 +/- 8 beats/min) (baseline to 60 min infusion time points).",Pharmacodynamics and pharmacokinetics of milrinone administration to increase oxygen delivery in critically ill patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8625682/),[beats] / [min],112,240,DB01427,Amrinone
,8625682,CI,"At the end of the 10-min loading dose, CI increased 0.3 L/min/m2 in the LOW group, 1.1 L/min/m2 in the MED group, and 0.9 L/min/m2 in the HIGH group.",Pharmacodynamics and pharmacokinetics of milrinone administration to increase oxygen delivery in critically ill patients. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8625682/),[l] / [m2·min],0.3,241,DB01427,Amrinone
,8625682,CI,"At the end of the 10-min loading dose, CI increased 0.3 L/min/m2 in the LOW group, 1.1 L/min/m2 in the MED group, and 0.9 L/min/m2 in the HIGH group.",Pharmacodynamics and pharmacokinetics of milrinone administration to increase oxygen delivery in critically ill patients. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8625682/),[l] / [m2·min],1.1,242,DB01427,Amrinone
,8625682,CI,"At the end of the 10-min loading dose, CI increased 0.3 L/min/m2 in the LOW group, 1.1 L/min/m2 in the MED group, and 0.9 L/min/m2 in the HIGH group.",Pharmacodynamics and pharmacokinetics of milrinone administration to increase oxygen delivery in critically ill patients. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8625682/),[l] / [m2·min],0.9,243,DB01427,Amrinone
,8625682,Peak plasma milrinone concentrations,"Peak plasma milrinone concentrations increased as a function of the loading dose (159 +/- 9 ng/mL in the LOW group, 302 +/- 33 ng/ml in the MED group, and 411 +/- 45 ng/mL in the HIGH group).",Pharmacodynamics and pharmacokinetics of milrinone administration to increase oxygen delivery in critically ill patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8625682/),[ng] / [ml],159,244,DB01427,Amrinone
,8625682,Peak plasma milrinone concentrations,"Peak plasma milrinone concentrations increased as a function of the loading dose (159 +/- 9 ng/mL in the LOW group, 302 +/- 33 ng/ml in the MED group, and 411 +/- 45 ng/mL in the HIGH group).",Pharmacodynamics and pharmacokinetics of milrinone administration to increase oxygen delivery in critically ill patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8625682/),[ng] / [ml],302,245,DB01427,Amrinone
,8625682,Peak plasma milrinone concentrations,"Peak plasma milrinone concentrations increased as a function of the loading dose (159 +/- 9 ng/mL in the LOW group, 302 +/- 33 ng/ml in the MED group, and 411 +/- 45 ng/mL in the HIGH group).",Pharmacodynamics and pharmacokinetics of milrinone administration to increase oxygen delivery in critically ill patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8625682/),[ng] / [ml],411,246,DB01427,Amrinone
,8625682,concentrations,"However, milrinone concentrations were similar in all three groups after the 1-h infusion; 113 +/- 14 ng/ml (LOW), 147 +/- 22 ng/mL (MED), and 119 +/- 14 ng/ml (HIGH).",Pharmacodynamics and pharmacokinetics of milrinone administration to increase oxygen delivery in critically ill patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8625682/),[ng] / [ml],113,247,DB01427,Amrinone
,8625682,concentrations,"However, milrinone concentrations were similar in all three groups after the 1-h infusion; 113 +/- 14 ng/ml (LOW), 147 +/- 22 ng/mL (MED), and 119 +/- 14 ng/ml (HIGH).",Pharmacodynamics and pharmacokinetics of milrinone administration to increase oxygen delivery in critically ill patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8625682/),[ng] / [ml],147,248,DB01427,Amrinone
,8625682,concentrations,"However, milrinone concentrations were similar in all three groups after the 1-h infusion; 113 +/- 14 ng/ml (LOW), 147 +/- 22 ng/mL (MED), and 119 +/- 14 ng/ml (HIGH).",Pharmacodynamics and pharmacokinetics of milrinone administration to increase oxygen delivery in critically ill patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8625682/),[ng] / [ml],119,249,DB01427,Amrinone
,8625682,adequate plasma concentrations,"Our study confirms that a milrinone loading dose of 50 micrograms/kg/min followed by an infusion of 0.5 microgram/kg/min achieves adequate plasma concentrations of 100 ng/mL or greater, which significantly increases both CI and Do2.",Pharmacodynamics and pharmacokinetics of milrinone administration to increase oxygen delivery in critically ill patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8625682/),,100,250,DB01427,Amrinone
,7669958,Need for,Need for NE during the loading infusion was 9.6 +/- 4.9 micrograms (mean +/- SEM) in group 1 and 41.6 +/- 7.6 micrograms in group 2 (p = 0.004).,Comparison of two different loading doses of milrinone for weaning from cardiopulmonary bypass. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7669958/),μg,9.6,1547,DB01427,Amrinone
,7669958,Need for,Need for NE during the loading infusion was 9.6 +/- 4.9 micrograms (mean +/- SEM) in group 1 and 41.6 +/- 7.6 micrograms in group 2 (p = 0.004).,Comparison of two different loading doses of milrinone for weaning from cardiopulmonary bypass. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7669958/),μg,41.6,1548,DB01427,Amrinone
,7669958,NE,Need for NE during the loading infusion was 9.6 +/- 4.9 micrograms (mean +/- SEM) in group 1 and 41.6 +/- 7.6 micrograms in group 2 (p = 0.004).,Comparison of two different loading doses of milrinone for weaning from cardiopulmonary bypass. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7669958/),μg,9.6,1549,DB01427,Amrinone
,7669958,NE,Need for NE during the loading infusion was 9.6 +/- 4.9 micrograms (mean +/- SEM) in group 1 and 41.6 +/- 7.6 micrograms in group 2 (p = 0.004).,Comparison of two different loading doses of milrinone for weaning from cardiopulmonary bypass. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7669958/),μg,41.6,1550,DB01427,Amrinone
,7669958,Need,Need for NE during the immediate post-CPB period was also higher in group 2 (16.0 +/- 10.4 micrograms in group 1 and 232.5 +/- 82.8 micrograms in group 2 (p = 0.002)).,Comparison of two different loading doses of milrinone for weaning from cardiopulmonary bypass. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7669958/),μg,16.0,1551,DB01427,Amrinone
,7669958,Need,Need for NE during the immediate post-CPB period was also higher in group 2 (16.0 +/- 10.4 micrograms in group 1 and 232.5 +/- 82.8 micrograms in group 2 (p = 0.002)).,Comparison of two different loading doses of milrinone for weaning from cardiopulmonary bypass. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7669958/),μg,232.5,1552,DB01427,Amrinone
,7669958,NE,Need for NE during the immediate post-CPB period was also higher in group 2 (16.0 +/- 10.4 micrograms in group 1 and 232.5 +/- 82.8 micrograms in group 2 (p = 0.002)).,Comparison of two different loading doses of milrinone for weaning from cardiopulmonary bypass. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7669958/),μg,16.0,1553,DB01427,Amrinone
,7669958,NE,Need for NE during the immediate post-CPB period was also higher in group 2 (16.0 +/- 10.4 micrograms in group 1 and 232.5 +/- 82.8 micrograms in group 2 (p = 0.002)).,Comparison of two different loading doses of milrinone for weaning from cardiopulmonary bypass. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7669958/),μg,232.5,1554,DB01427,Amrinone
,2752768,T1/2,"T1/2(22.2 vs. 6.8 h) and clearance (1.1 vs. 2.6 ml/min.kg), but not the volume of distribution (1.8 vs. 1.6 L/kg), differed significantly in patients less than 4 wk of age in comparison to patients greater than 4 wk of age.",Amrinone in neonates and infants after cardiac surgery. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2752768/),h,22.2,3769,DB01427,Amrinone
,2752768,T1/2,"T1/2(22.2 vs. 6.8 h) and clearance (1.1 vs. 2.6 ml/min.kg), but not the volume of distribution (1.8 vs. 1.6 L/kg), differed significantly in patients less than 4 wk of age in comparison to patients greater than 4 wk of age.",Amrinone in neonates and infants after cardiac surgery. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2752768/),h,6.8,3770,DB01427,Amrinone
,2752768,clearance,"T1/2(22.2 vs. 6.8 h) and clearance (1.1 vs. 2.6 ml/min.kg), but not the volume of distribution (1.8 vs. 1.6 L/kg), differed significantly in patients less than 4 wk of age in comparison to patients greater than 4 wk of age.",Amrinone in neonates and infants after cardiac surgery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2752768/),[ml] / [kg·min],1.1,3771,DB01427,Amrinone
,2752768,clearance,"T1/2(22.2 vs. 6.8 h) and clearance (1.1 vs. 2.6 ml/min.kg), but not the volume of distribution (1.8 vs. 1.6 L/kg), differed significantly in patients less than 4 wk of age in comparison to patients greater than 4 wk of age.",Amrinone in neonates and infants after cardiac surgery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2752768/),[ml] / [kg·min],2.6,3772,DB01427,Amrinone
,2752768,volume of distribution,"T1/2(22.2 vs. 6.8 h) and clearance (1.1 vs. 2.6 ml/min.kg), but not the volume of distribution (1.8 vs. 1.6 L/kg), differed significantly in patients less than 4 wk of age in comparison to patients greater than 4 wk of age.",Amrinone in neonates and infants after cardiac surgery. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2752768/),[l] / [kg],1.8,3773,DB01427,Amrinone
,2752768,volume of distribution,"T1/2(22.2 vs. 6.8 h) and clearance (1.1 vs. 2.6 ml/min.kg), but not the volume of distribution (1.8 vs. 1.6 L/kg), differed significantly in patients less than 4 wk of age in comparison to patients greater than 4 wk of age.",Amrinone in neonates and infants after cardiac surgery. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2752768/),[l] / [kg],1.6,3774,DB01427,Amrinone
,4050707,clearance,"Mean plasma milrinone clearance (+/- standard error) was 0.15 +/- 0.03 liters/min/kg, volume of distribution was 0.35 +/- 0.02 liters/kg and mean elimination half-life was 1.7 hours.",Pharmacokinetics and pharmacodynamics of milrinone in chronic congestive heart failure. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4050707/),[l] / [kg·min],0.15,7911,DB01427,Amrinone
,4050707,volume of distribution,"Mean plasma milrinone clearance (+/- standard error) was 0.15 +/- 0.03 liters/min/kg, volume of distribution was 0.35 +/- 0.02 liters/kg and mean elimination half-life was 1.7 hours.",Pharmacokinetics and pharmacodynamics of milrinone in chronic congestive heart failure. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4050707/),[l] / [kg],0.35,7912,DB01427,Amrinone
,4050707,elimination half-life,"Mean plasma milrinone clearance (+/- standard error) was 0.15 +/- 0.03 liters/min/kg, volume of distribution was 0.35 +/- 0.02 liters/kg and mean elimination half-life was 1.7 hours.",Pharmacokinetics and pharmacodynamics of milrinone in chronic congestive heart failure. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/4050707/),h,1.7,7913,DB01427,Amrinone
,7621849,sieving coefficient (S),"We found significant amrinone clearance, with a mean sieving coefficient (S) of 0.44%, which correlates with the protein-unbound, pharmacologically effective fraction of amrinone.",Elimination of amrinone during continuous veno-venous haemofiltration after cardiac surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7621849/),%,0.44,14732,DB01427,Amrinone
,3589153,peak plasma concentrations,Mean (SD) peak plasma concentrations of amrinone (2.1 (1.1) mcg/ml) were obtained 0.5 to 2 hours after drug administration.,Pharmacokinetics and hemodynamics of amrinone in patients with chronic cardiac failure of diverse etiology. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3589153/),[mcg] / [ml],2.1,21328,DB01427,Amrinone
,3589153,apparent oral clearance,"The mean (SD) apparent oral clearance, apparent volume of distribution at steady state and half-life of amrinone were 0.23 (0.13) L/hr/kg, 1.2 (0.4) L/kg, and 4.8 (3.0) hr.",Pharmacokinetics and hemodynamics of amrinone in patients with chronic cardiac failure of diverse etiology. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3589153/),[l] / [h·kg],0.23,21329,DB01427,Amrinone
,3589153,apparent volume of distribution at steady state,"The mean (SD) apparent oral clearance, apparent volume of distribution at steady state and half-life of amrinone were 0.23 (0.13) L/hr/kg, 1.2 (0.4) L/kg, and 4.8 (3.0) hr.",Pharmacokinetics and hemodynamics of amrinone in patients with chronic cardiac failure of diverse etiology. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3589153/),[l] / [kg],1.2,21330,DB01427,Amrinone
,3589153,half-life,"The mean (SD) apparent oral clearance, apparent volume of distribution at steady state and half-life of amrinone were 0.23 (0.13) L/hr/kg, 1.2 (0.4) L/kg, and 4.8 (3.0) hr.",Pharmacokinetics and hemodynamics of amrinone in patients with chronic cardiac failure of diverse etiology. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3589153/),h,4.8,21331,DB01427,Amrinone
,10201672,peak plasma concentration,The loading dose of milrinone resulted in a mean decrease in mean blood pressure of 12% and a mean increase in cardiac index of 18% at a mean peak plasma concentration of 235 ng/ml.,The pharmacokinetics of milrinone in pediatric patients after cardiac surgery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10201672/),[ng] / [ml],235,26549,DB01427,Amrinone
,2521045,elimination half-life,"The elimination half-life in healthy patients is reported to be 2.6 to 4.1 hours, making it the only long-acting positive inotropic agent available that can be administered either as an intravenous bolus or by infusion.",Amrinone: pharmacokinetics and pharmacodynamics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2521045/),h,2.6 to 4.1,26825,DB01427,Amrinone
,9506650,plasma concentration at steady-state (Css avg),"The average plasma concentration at steady-state (Css avg) and total body clearance for phase 1 were 81.3+/-38.6 ng/ml (mean +/- SD) and 0.0106+/-0.0053 L/kg/min, respectively (n = 9).",Pharmacokinetics and pharmacodynamics of milrinone lactate in pediatric patients with septic shock. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9506650/),[ng] / [ml],81.3,31397,DB01427,Amrinone
,9506650,total body clearance,"The average plasma concentration at steady-state (Css avg) and total body clearance for phase 1 were 81.3+/-38.6 ng/ml (mean +/- SD) and 0.0106+/-0.0053 L/kg/min, respectively (n = 9).",Pharmacokinetics and pharmacodynamics of milrinone lactate in pediatric patients with septic shock. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9506650/),[l] / [kg·min],0.0106,31398,DB01427,Amrinone
,9506650,Css avg,"In phase 2 Css avg and total body clearance were 65.8+/-42.1 ng/ml and 0.0110+/-0.0096 L/kg/min, respectively (n = 11).",Pharmacokinetics and pharmacodynamics of milrinone lactate in pediatric patients with septic shock. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9506650/),[ng] / [ml],65.8,31399,DB01427,Amrinone
,9506650,total body clearance,"In phase 2 Css avg and total body clearance were 65.8+/-42.1 ng/ml and 0.0110+/-0.0096 L/kg/min, respectively (n = 11).",Pharmacokinetics and pharmacodynamics of milrinone lactate in pediatric patients with septic shock. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9506650/),[l] / [kg·min],0.0110,31400,DB01427,Amrinone
,9506650,time of infusion,The average time of infusion was 51+/-21 hours.,Pharmacokinetics and pharmacodynamics of milrinone lactate in pediatric patients with septic shock. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9506650/),h,51,31401,DB01427,Amrinone
,9506650,elimination rate constant,The mean elimination rate constant was 0.0091+/-0.0061 min(-1) (n = 8).,Pharmacokinetics and pharmacodynamics of milrinone lactate in pediatric patients with septic shock. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9506650/),1/[min],0.0091,31402,DB01427,Amrinone
,9506650,half-life,"The median half-life was 1.47 hours (range, 0.62 to 10.85 hours).",Pharmacokinetics and pharmacodynamics of milrinone lactate in pediatric patients with septic shock. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9506650/),h,1.47,31403,DB01427,Amrinone
,9506650,volume of distribution at steady-state,The volume of distribution at steady-state was 1.47+/-1.03 L/kg.,Pharmacokinetics and pharmacodynamics of milrinone lactate in pediatric patients with septic shock. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9506650/),[l] / [kg],1.47,31404,DB01427,Amrinone
,9506650,Css avg,All patients achieved at least a 20% change in cardiac index and systemic vascular resistance index while maintaining a Css avg of 35 to 160 ng/ml.,Pharmacokinetics and pharmacodynamics of milrinone lactate in pediatric patients with septic shock. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9506650/),[ng] / [ml],35 to 160,31405,DB01427,Amrinone
,9506650,half-life,"Because the median half-life is 1.47 hours, immediate hemodynamic effects may not be seen unless appropriate loading doses and infusion adjustments are made.",Pharmacokinetics and pharmacodynamics of milrinone lactate in pediatric patients with septic shock. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9506650/),h,1.47,31406,DB01427,Amrinone
,8092507,Central-compartment volume,"Central-compartment volume was 102 ml/kg, volume of distribution was 1,698 ml/kg, and elimination clearance was 1.88 ml.kg-1.min-1.",Pharmacokinetics of intravenous milrinone in patients undergoing cardiac surgery. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8092507/),[ml] / [kg],102,48428,DB01427,Amrinone
,8092507,volume of distribution,"Central-compartment volume was 102 ml/kg, volume of distribution was 1,698 ml/kg, and elimination clearance was 1.88 ml.kg-1.min-1.",Pharmacokinetics of intravenous milrinone in patients undergoing cardiac surgery. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8092507/),[ml] / [kg],"1,698",48429,DB01427,Amrinone
,8092507,elimination clearance,"Central-compartment volume was 102 ml/kg, volume of distribution was 1,698 ml/kg, and elimination clearance was 1.88 ml.kg-1.min-1.",Pharmacokinetics of intravenous milrinone in patients undergoing cardiac surgery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8092507/),[ml] / [kg·min],1.88,48430,DB01427,Amrinone
< or =,8205809,steady-state plasma amrinone concentrations,Six (19.4%) of 31 patients had steady-state plasma amrinone concentrations of < or = 2 micrograms/mL.,Age-related amrinone pharmacokinetics in a pediatric population. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8205809/),[μg] / [ml],2,59746,DB01427,Amrinone
,8205809,Renal clearance,"Renal clearance of amrinone ranged between 0.4 and 2.18 mL/kg/min, and did not increase with age.",Age-related amrinone pharmacokinetics in a pediatric population. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8205809/),[ml] / [kg·min],0.4 and 2.18,59747,DB01427,Amrinone
greater,16615956,flow,The primary outcome was maintenance of SVC flow greater than 45 mL/kg per minute through the first 24 hours.,Pilot study of milrinone for low systemic blood flow in very preterm infants. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16615956/),[ml] / [kg·min],45,60266,DB01427,Amrinone
,3906583,elimination half-life,"Pharmacokinetic studies of amrinone report an elimination half-life of 2.6-8.3 hours, with slower elimination more likely in patients with compromised renal or hepatic function.",Evaluation of intravenous amrinone: the first of a new class of positive inotropic agents with vasodilator properties. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3906583/),h,2.6-8.3,64003,DB01427,Amrinone
,27490706,target plasma concentration,The target plasma concentration was set at 150-200 ng/ml.,Dosing of Milrinone in Preterm Neonates to Prevent Postligation Cardiac Syndrome: Simulation Study Suggests Need for Bolus Infusion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27490706/),[ng] / [ml],150-200,64705,DB01427,Amrinone
,30664589,clearance,Parameter estimates for a patient with the median weight were 0.350 (L/hr) for clearance and 0.329 (L) for volume of distribution.,Population Pharmacokinetics and Dosing of Milrinone After Patent Ductus Arteriosus Ligation in Preterm Infants. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30664589/),[l] / [h],0.350,66407,DB01427,Amrinone
,30664589,volume of distribution,Parameter estimates for a patient with the median weight were 0.350 (L/hr) for clearance and 0.329 (L) for volume of distribution.,Population Pharmacokinetics and Dosing of Milrinone After Patent Ductus Arteriosus Ligation in Preterm Infants. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30664589/),l,0.329,66408,DB01427,Amrinone
,3145204,plasma AUC0 infinity,"The mean plasma AUC0 infinity was determined at each dose level; the values obtained were 2.5, 18.7, 33.9, 103 and 312 micrograms.",The relationship between the pharmacokinetics of amrinone in the marmoset and platelet effects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3145204/),μg,2.5,84273,DB01427,Amrinone
,3145204,plasma AUC0 infinity,"The mean plasma AUC0 infinity was determined at each dose level; the values obtained were 2.5, 18.7, 33.9, 103 and 312 micrograms.",The relationship between the pharmacokinetics of amrinone in the marmoset and platelet effects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3145204/),μg,18.7,84274,DB01427,Amrinone
,3145204,plasma AUC0 infinity,"The mean plasma AUC0 infinity was determined at each dose level; the values obtained were 2.5, 18.7, 33.9, 103 and 312 micrograms.",The relationship between the pharmacokinetics of amrinone in the marmoset and platelet effects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3145204/),μg,33.9,84275,DB01427,Amrinone
,3145204,plasma AUC0 infinity,"The mean plasma AUC0 infinity was determined at each dose level; the values obtained were 2.5, 18.7, 33.9, 103 and 312 micrograms.",The relationship between the pharmacokinetics of amrinone in the marmoset and platelet effects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3145204/),μg,103,84276,DB01427,Amrinone
,3145204,plasma AUC0 infinity,"The mean plasma AUC0 infinity was determined at each dose level; the values obtained were 2.5, 18.7, 33.9, 103 and 312 micrograms.",The relationship between the pharmacokinetics of amrinone in the marmoset and platelet effects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3145204/),μg,312,84277,DB01427,Amrinone
,3145204,maximum observed plasma concentrations,"Mean maximum observed plasma concentrations were 0.6, 7.1, 11.7, 23.7 and 40.0 micrograms.",The relationship between the pharmacokinetics of amrinone in the marmoset and platelet effects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3145204/),μg,0.6,84278,DB01427,Amrinone
,3145204,maximum observed plasma concentrations,"Mean maximum observed plasma concentrations were 0.6, 7.1, 11.7, 23.7 and 40.0 micrograms.",The relationship between the pharmacokinetics of amrinone in the marmoset and platelet effects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3145204/),μg,7.1,84279,DB01427,Amrinone
,3145204,maximum observed plasma concentrations,"Mean maximum observed plasma concentrations were 0.6, 7.1, 11.7, 23.7 and 40.0 micrograms.",The relationship between the pharmacokinetics of amrinone in the marmoset and platelet effects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3145204/),μg,11.7,84280,DB01427,Amrinone
,3145204,maximum observed plasma concentrations,"Mean maximum observed plasma concentrations were 0.6, 7.1, 11.7, 23.7 and 40.0 micrograms.",The relationship between the pharmacokinetics of amrinone in the marmoset and platelet effects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3145204/),μg,23.7,84281,DB01427,Amrinone
,3145204,maximum observed plasma concentrations,"Mean maximum observed plasma concentrations were 0.6, 7.1, 11.7, 23.7 and 40.0 micrograms.",The relationship between the pharmacokinetics of amrinone in the marmoset and platelet effects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3145204/),μg,40.0,84282,DB01427,Amrinone
,3145204,t1/2,kg-1 and the t1/2 in the marmoset was approximately 1 to 3 hours over this dose range.,The relationship between the pharmacokinetics of amrinone in the marmoset and platelet effects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3145204/),h,1 to 3,84283,DB01427,Amrinone
,7574011,V1,"Using mixed-effects nonlinear regression (for n = 28), the following volumes were determined for the three compartments: V1 = 11.1 L, V2 = 16.9 L, and V3 = 363 L.",A pharmacokinetic and pharmacodynamic evaluation of milrinone in adults undergoing cardiac surgery. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7574011/),l,11.1,131035,DB01427,Amrinone
,7574011,V2,"Using mixed-effects nonlinear regression (for n = 28), the following volumes were determined for the three compartments: V1 = 11.1 L, V2 = 16.9 L, and V3 = 363 L.",A pharmacokinetic and pharmacodynamic evaluation of milrinone in adults undergoing cardiac surgery. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7574011/),l,16.9,131036,DB01427,Amrinone
,7574011,V3,"Using mixed-effects nonlinear regression (for n = 28), the following volumes were determined for the three compartments: V1 = 11.1 L, V2 = 16.9 L, and V3 = 363 L.",A pharmacokinetic and pharmacodynamic evaluation of milrinone in adults undergoing cardiac surgery. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7574011/),l,363,131037,DB01427,Amrinone
,7574011,Cl1,"Similarly, the following clearances were estimated for the three compartments: Cl1 = 0.067 L/min, Cl2 = 1.05 L/min, and Cl3 = 0.31 L/min.",A pharmacokinetic and pharmacodynamic evaluation of milrinone in adults undergoing cardiac surgery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7574011/),[l] / [min],0.067,131038,DB01427,Amrinone
,7574011,Cl2,"Similarly, the following clearances were estimated for the three compartments: Cl1 = 0.067 L/min, Cl2 = 1.05 L/min, and Cl3 = 0.31 L/min.",A pharmacokinetic and pharmacodynamic evaluation of milrinone in adults undergoing cardiac surgery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7574011/),[l] / [min],1.05,131039,DB01427,Amrinone
,7574011,Cl3,"Similarly, the following clearances were estimated for the three compartments: Cl1 = 0.067 L/min, Cl2 = 1.05 L/min, and Cl3 = 0.31 L/min.",A pharmacokinetic and pharmacodynamic evaluation of milrinone in adults undergoing cardiac surgery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7574011/),[l] / [min],0.31,131040,DB01427,Amrinone
,7574011,half-times,The short context-sensitive half-times of 6.7 or 10.2 min after 1- or 10-min bolus infusions underscore the need for prompt institution of a maintenance infusion when milrinone concentrations must be maintained.,A pharmacokinetic and pharmacodynamic evaluation of milrinone in adults undergoing cardiac surgery. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7574011/),min,6.7,131041,DB01427,Amrinone
,7574011,half-times,The short context-sensitive half-times of 6.7 or 10.2 min after 1- or 10-min bolus infusions underscore the need for prompt institution of a maintenance infusion when milrinone concentrations must be maintained.,A pharmacokinetic and pharmacodynamic evaluation of milrinone in adults undergoing cardiac surgery. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7574011/),min,10.2,131042,DB01427,Amrinone
,7728786,peak milrinone concentration,"Dose-dependent hemodynamic response was observed between the drug concentration and percent maximum changes in pulmonary capillary wedge pressure (peak milrinone concentration, 2.5 mg: 99.99 +/- 57.49, 5 mg: 187.11 +/- 71.37, and 10 mg: 300.94 +/- 158.5 ng/ml).",Hemodynamic effects and pharmacokinetics of oral milrinone for short-term support in acute heart failure. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7728786/),[ng] / [ml],99.99,131175,DB01427,Amrinone
,7728786,peak milrinone concentration,"Dose-dependent hemodynamic response was observed between the drug concentration and percent maximum changes in pulmonary capillary wedge pressure (peak milrinone concentration, 2.5 mg: 99.99 +/- 57.49, 5 mg: 187.11 +/- 71.37, and 10 mg: 300.94 +/- 158.5 ng/ml).",Hemodynamic effects and pharmacokinetics of oral milrinone for short-term support in acute heart failure. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7728786/),[ng] / [ml],187.11,131176,DB01427,Amrinone
,7728786,peak milrinone concentration,"Dose-dependent hemodynamic response was observed between the drug concentration and percent maximum changes in pulmonary capillary wedge pressure (peak milrinone concentration, 2.5 mg: 99.99 +/- 57.49, 5 mg: 187.11 +/- 71.37, and 10 mg: 300.94 +/- 158.5 ng/ml).",Hemodynamic effects and pharmacokinetics of oral milrinone for short-term support in acute heart failure. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7728786/),[ng] / [ml],300.94,131177,DB01427,Amrinone
,8583366,clearance,"This was followed by an 18 h maintenance infusion of milrinone at 0.45 or 0.35 micrograms kg-1 min-1 for the moderate (chromium-EDTA clearance of 31-75 mL min-1, n = 10) and severe renally impaired subjects (chromium-EDTA of clearance 10-30 mL min-1, n = 11), respectively.",Dose regimen adjustment for milrinone in congestive heart failure patients with moderate and severe renal failure. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8583366/),[ml] / [min],31-75,134452,DB01427,Amrinone
,8583366,of clearance,"This was followed by an 18 h maintenance infusion of milrinone at 0.45 or 0.35 micrograms kg-1 min-1 for the moderate (chromium-EDTA clearance of 31-75 mL min-1, n = 10) and severe renally impaired subjects (chromium-EDTA of clearance 10-30 mL min-1, n = 11), respectively.",Dose regimen adjustment for milrinone in congestive heart failure patients with moderate and severe renal failure. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8583366/),[ml] / [min],10-30,134453,DB01427,Amrinone
,8583366,steady-state plasma concentrations,"The mean (+/- s.d.) steady-state plasma concentrations of milrinone were within the therapeutic range (100-300 ng mL-1) for both groups, with values of 239 +/- 71 ng mL-1 and 269 +/- 32 ng mL-1 for the moderate and severe patients, respectively.",Dose regimen adjustment for milrinone in congestive heart failure patients with moderate and severe renal failure. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8583366/),[ng] / [ml],100-300,134454,DB01427,Amrinone
,8583366,steady-state plasma concentrations,"The mean (+/- s.d.) steady-state plasma concentrations of milrinone were within the therapeutic range (100-300 ng mL-1) for both groups, with values of 239 +/- 71 ng mL-1 and 269 +/- 32 ng mL-1 for the moderate and severe patients, respectively.",Dose regimen adjustment for milrinone in congestive heart failure patients with moderate and severe renal failure. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8583366/),[ng] / [ml],239,134455,DB01427,Amrinone
,8583366,steady-state plasma concentrations,"The mean (+/- s.d.) steady-state plasma concentrations of milrinone were within the therapeutic range (100-300 ng mL-1) for both groups, with values of 239 +/- 71 ng mL-1 and 269 +/- 32 ng mL-1 for the moderate and severe patients, respectively.",Dose regimen adjustment for milrinone in congestive heart failure patients with moderate and severe renal failure. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8583366/),[ng] / [ml],269,134456,DB01427,Amrinone
,8583366,steady-state levels,"Those outside the nominal range showed steady-state levels, ranging between 308 and 353 ng mL-1, that were not associated with any serious adverse events.",Dose regimen adjustment for milrinone in congestive heart failure patients with moderate and severe renal failure. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8583366/),[ng] / [ml],308 and 353,134457,DB01427,Amrinone
,7174852,tmax,"Amrinone was absorbed quickly (tmax = 1.4 hour), and the disappearance of amrinone from serum was log-linear (t1/2 = 5.1 hours).",Acute pharmacodynamics and pharmacokinetics of oral amrinone. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7174852/),h,1.4,135102,DB01427,Amrinone
,7174852,t1/2,"Amrinone was absorbed quickly (tmax = 1.4 hour), and the disappearance of amrinone from serum was log-linear (t1/2 = 5.1 hours).",Acute pharmacodynamics and pharmacokinetics of oral amrinone. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7174852/),h,5.1,135103,DB01427,Amrinone
,8268437,clearance,"Pharmacokinetic analysis in 12 children showed a clearance of 3.4 mL/min/kg, a volume of distribution of 1.65 L/kg, and an elimination half-life of 5.75 hours.",Hemodynamic effects of amrinone and colloid administration in children following cardiac surgery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8268437/),[ml] / [kg·min],3.4,137464,DB01427,Amrinone
,8268437,volume of distribution,"Pharmacokinetic analysis in 12 children showed a clearance of 3.4 mL/min/kg, a volume of distribution of 1.65 L/kg, and an elimination half-life of 5.75 hours.",Hemodynamic effects of amrinone and colloid administration in children following cardiac surgery. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8268437/),[l] / [kg],1.65,137465,DB01427,Amrinone
,8268437,elimination half-life,"Pharmacokinetic analysis in 12 children showed a clearance of 3.4 mL/min/kg, a volume of distribution of 1.65 L/kg, and an elimination half-life of 5.75 hours.",Hemodynamic effects of amrinone and colloid administration in children following cardiac surgery. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8268437/),h,5.75,137466,DB01427,Amrinone
,2338634,Half-times,"Half-times were 20.6 +/- 5.5 min (0.3 mg/kg milrinone), 17.0 +/- 1.8 min (1.0 mg/kg), 31.4 +/- 4.5 min (3.0 mg/kg), and 95.5 +/- 18.4 min (10.0 mg/kg).",Plasma elimination of milrinone in rats in relation to its hemodynamic effects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2338634/),min,20.6,140334,DB01427,Amrinone
,2338634,Half-times,"Half-times were 20.6 +/- 5.5 min (0.3 mg/kg milrinone), 17.0 +/- 1.8 min (1.0 mg/kg), 31.4 +/- 4.5 min (3.0 mg/kg), and 95.5 +/- 18.4 min (10.0 mg/kg).",Plasma elimination of milrinone in rats in relation to its hemodynamic effects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2338634/),min,17.0,140335,DB01427,Amrinone
,2338634,Half-times,"Half-times were 20.6 +/- 5.5 min (0.3 mg/kg milrinone), 17.0 +/- 1.8 min (1.0 mg/kg), 31.4 +/- 4.5 min (3.0 mg/kg), and 95.5 +/- 18.4 min (10.0 mg/kg).",Plasma elimination of milrinone in rats in relation to its hemodynamic effects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2338634/),min,31.4,140336,DB01427,Amrinone
,2338634,Half-times,"Half-times were 20.6 +/- 5.5 min (0.3 mg/kg milrinone), 17.0 +/- 1.8 min (1.0 mg/kg), 31.4 +/- 4.5 min (3.0 mg/kg), and 95.5 +/- 18.4 min (10.0 mg/kg).",Plasma elimination of milrinone in rats in relation to its hemodynamic effects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2338634/),min,95.5,140337,DB01427,Amrinone
,2338634,half-effective plasma concentration,The half-effective plasma concentration of milrinone was 1.0 +/- 0.2 microM.,Plasma elimination of milrinone in rats in relation to its hemodynamic effects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2338634/),μM,1.0,140338,DB01427,Amrinone
,1600963,elimination half-life,"The elimination half-life of amrinone in volunteers is 2.6-4.1 h, and 3.5 h when administered into the cardiopulmonary bypass (CPB) circuit.",Perioperative experience with amrinone. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1600963/),h,2.6-4.1,141058,DB01427,Amrinone
,1600963,elimination half-life,"The elimination half-life of amrinone in volunteers is 2.6-4.1 h, and 3.5 h when administered into the cardiopulmonary bypass (CPB) circuit.",Perioperative experience with amrinone. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1600963/),h,3.5,141059,DB01427,Amrinone
,15346851,volume of distribution,The volume of distribution was 482 ml kg(-1) and was independent of age.,A population pharmacokinetic analysis of milrinone in pediatric patients after cardiac surgery. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15346851/),[ml] / [kg],482,148209,DB01427,Amrinone
,15346851,Cl,Clearance was a linear function of age given by Cl = 2.42 ml kg(-1) min(-1) [1 + 0.396*age].,A population pharmacokinetic analysis of milrinone in pediatric patients after cardiac surgery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15346851/),[ml] / [kg·min],2.42,148210,DB01427,Amrinone
,3956560,urinary recovery,"The mean urinary recovery of milrinone was 82% in healthy subjects, the renal clearance was 288 ml/min and the plasma half-life (t1/2) was 0.94 h.",Pharmacokinetics and effects on blood pressure of a single oral dose of milrinone in healthy subjects and in patients with renal impairment. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3956560/),%,82,164112,DB01427,Amrinone
,3956560,renal clearance,"The mean urinary recovery of milrinone was 82% in healthy subjects, the renal clearance was 288 ml/min and the plasma half-life (t1/2) was 0.94 h.",Pharmacokinetics and effects on blood pressure of a single oral dose of milrinone in healthy subjects and in patients with renal impairment. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3956560/),[ml] / [min],288,164113,DB01427,Amrinone
,3956560,plasma half-life (t1/2),"The mean urinary recovery of milrinone was 82% in healthy subjects, the renal clearance was 288 ml/min and the plasma half-life (t1/2) was 0.94 h.",Pharmacokinetics and effects on blood pressure of a single oral dose of milrinone in healthy subjects and in patients with renal impairment. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3956560/),h,0.94,164114,DB01427,Amrinone
,3956560,plasma t1/2,"In CRI the mean plasma t1/2 was prolonged (CRI I 1.78 h, CRI II 3.24 h).",Pharmacokinetics and effects on blood pressure of a single oral dose of milrinone in healthy subjects and in patients with renal impairment. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3956560/),h,1.78,164115,DB01427,Amrinone
,3956560,plasma t1/2,"In CRI the mean plasma t1/2 was prolonged (CRI I 1.78 h, CRI II 3.24 h).",Pharmacokinetics and effects on blood pressure of a single oral dose of milrinone in healthy subjects and in patients with renal impairment. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3956560/),h,3.24,164116,DB01427,Amrinone
,6502494,bioavailability,"The mean bioavailability, based on the area under the plasma concentration versus time curves, was 0.92.",Oral and intravenous pharmacokinetics of milrinone in human volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6502494/),,0.92,164360,DB01427,Amrinone
,6502494,apparent first-order terminal elimination rate constant (beta),"The plasma data for those subjects in the intravenous study were described by an open two-compartment model with a mean (+/- SD) apparent first-order terminal elimination rate constant (beta) of 0.86 (+/- 0.23) h-1, which corresponds to a half-life of 0.8 h.",Oral and intravenous pharmacokinetics of milrinone in human volunteers. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6502494/),1/[h],0.86,164361,DB01427,Amrinone
,6502494,half-life,"The plasma data for those subjects in the intravenous study were described by an open two-compartment model with a mean (+/- SD) apparent first-order terminal elimination rate constant (beta) of 0.86 (+/- 0.23) h-1, which corresponds to a half-life of 0.8 h.",Oral and intravenous pharmacokinetics of milrinone in human volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6502494/),h,0.8,164362,DB01427,Amrinone
,6502494,renal clearance,"In the intravenous study, the renal clearance and total body clearance were 21.1 and 25.9 L/h, respectively.",Oral and intravenous pharmacokinetics of milrinone in human volunteers. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6502494/),[l] / [h],21.1,164363,DB01427,Amrinone
,6502494,total body clearance,"In the intravenous study, the renal clearance and total body clearance were 21.1 and 25.9 L/h, respectively.",Oral and intravenous pharmacokinetics of milrinone in human volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6502494/),[l] / [h],25.9,164364,DB01427,Amrinone
,3510771,apparent first-order terminal elimination half-life,"After either oral or parenteral administration of milrinone, plasma levels were dose dependent and the drug had an apparent first-order terminal elimination half-life of approximately 2 hr.",Pharmacokinetics of the bipyridines amrinone and milrinone. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3510771/),h,2,166746,DB01427,Amrinone
,3510771,apparent volume of distribution,"The apparent volume of distribution was approximately 400 to 500 ml/kg, and total body clearance was approximately 130 ml/kg/hr.",Pharmacokinetics of the bipyridines amrinone and milrinone. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3510771/),[ml] / [kg],400 to 500,166747,DB01427,Amrinone
,3510771,total body clearance,"The apparent volume of distribution was approximately 400 to 500 ml/kg, and total body clearance was approximately 130 ml/kg/hr.",Pharmacokinetics of the bipyridines amrinone and milrinone. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3510771/),[ml] / [h·kg],130,166748,DB01427,Amrinone
,11030165,steady-state concentration (Css),"The steady-state concentration (Css) was 845 +/- 135 (mean +/- SD) ng/ml, and the half-life time (t1/2) was 20.1 +/- 3.3 h.",Pharmacokinetics of milrinone in patients with congestive heart failure during continuous venovenous hemofiltration. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11030165/),[ng] / [ml],845,176238,DB01427,Amrinone
,11030165,half-life time (t1/2),"The steady-state concentration (Css) was 845 +/- 135 (mean +/- SD) ng/ml, and the half-life time (t1/2) was 20.1 +/- 3.3 h.",Pharmacokinetics of milrinone in patients with congestive heart failure during continuous venovenous hemofiltration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11030165/),h,20.1,176239,DB01427,Amrinone
,34350821,infusion rate,"We included 399 children with a median (quarter 1, quarter 3) age of 1 year (0,5) who received 428 intravenous doses of milrinone (median infusion rate 0.31 mcg/kg/min [0.29,0.5]).",The relationship between simulated milrinone exposure and hypotension in children. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34350821/),[mcg] / [kg·min],0.31,177904,DB01427,Amrinone
,34350821,maximum plasma milrinone concentration,"Median maximum plasma milrinone concentration was 110.7 ng/ml (48.4,206.2).",The relationship between simulated milrinone exposure and hypotension in children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34350821/),[ng] / [ml],110.7,177905,DB01427,Amrinone
,34350821,maximum simulated,"The maximum simulated milrinone plasma concentrations were higher in subjects with clinically significant hypotension (251 ng/ml [129,329]) versus with hypotension alone (86 ng/ml [44, 173]) versus without hypotension (122 ng/ml [57, 208], p = 0.002); however, this relationship was not retained on multivariable analysis (odds ratio 1.01; 95% confidence interval 0.998, 1.01).",The relationship between simulated milrinone exposure and hypotension in children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34350821/),[ng] / [ml],251,177906,DB01427,Amrinone
,34350821,maximum simulated,"The maximum simulated milrinone plasma concentrations were higher in subjects with clinically significant hypotension (251 ng/ml [129,329]) versus with hypotension alone (86 ng/ml [44, 173]) versus without hypotension (122 ng/ml [57, 208], p = 0.002); however, this relationship was not retained on multivariable analysis (odds ratio 1.01; 95% confidence interval 0.998, 1.01).",The relationship between simulated milrinone exposure and hypotension in children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34350821/),[ng] / [ml],86,177907,DB01427,Amrinone
,34350821,plasma concentrations,"The maximum simulated milrinone plasma concentrations were higher in subjects with clinically significant hypotension (251 ng/ml [129,329]) versus with hypotension alone (86 ng/ml [44, 173]) versus without hypotension (122 ng/ml [57, 208], p = 0.002); however, this relationship was not retained on multivariable analysis (odds ratio 1.01; 95% confidence interval 0.998, 1.01).",The relationship between simulated milrinone exposure and hypotension in children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34350821/),[ng] / [ml],251,177908,DB01427,Amrinone
,34350821,plasma concentrations,"The maximum simulated milrinone plasma concentrations were higher in subjects with clinically significant hypotension (251 ng/ml [129,329]) versus with hypotension alone (86 ng/ml [44, 173]) versus without hypotension (122 ng/ml [57, 208], p = 0.002); however, this relationship was not retained on multivariable analysis (odds ratio 1.01; 95% confidence interval 0.998, 1.01).",The relationship between simulated milrinone exposure and hypotension in children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34350821/),[ng] / [ml],86,177909,DB01427,Amrinone
,34350821,plasma concentrations,"The maximum simulated milrinone plasma concentrations were higher in subjects with clinically significant hypotension (251 ng/ml [129,329]) versus with hypotension alone (86 ng/ml [44, 173]) versus without hypotension (122 ng/ml [57, 208], p = 0.002); however, this relationship was not retained on multivariable analysis (odds ratio 1.01; 95% confidence interval 0.998, 1.01).",The relationship between simulated milrinone exposure and hypotension in children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34350821/),[ng] / [ml],122,177910,DB01427,Amrinone
,3780123,apparent first-order elimination t1/2,"The mean apparent first-order elimination t1/2 for amrinone in the slow acetylators was 4.4 hours, whereas it was 2.0 hours in the fast acetylators (P less than 0.05).",Effect of the acetylator phenotype on amrinone pharmacokinetics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3780123/),h,4.4,178589,DB01427,Amrinone
,3780123,apparent first-order elimination t1/2,"The mean apparent first-order elimination t1/2 for amrinone in the slow acetylators was 4.4 hours, whereas it was 2.0 hours in the fast acetylators (P less than 0.05).",Effect of the acetylator phenotype on amrinone pharmacokinetics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3780123/),h,2.0,178590,DB01427,Amrinone
,3780123,Clearance,"Clearance was lower in the slow acetylators, 16.6 L/hr, than in the fast acetylators, 37.2 L/hr (P less than 0.05).",Effect of the acetylator phenotype on amrinone pharmacokinetics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3780123/),[l] / [h],16.6,178591,DB01427,Amrinone
,3780123,Clearance,"Clearance was lower in the slow acetylators, 16.6 L/hr, than in the fast acetylators, 37.2 L/hr (P less than 0.05).",Effect of the acetylator phenotype on amrinone pharmacokinetics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3780123/),[l] / [h],37.2,178592,DB01427,Amrinone
,3780123,AUC,"The AUC was higher for the slow acetylators, 4.96 micrograms X hr X ml-1, than for the fast acetylators, 2.20 micrograms X hr X ml-1 (P less than 0.01).",Effect of the acetylator phenotype on amrinone pharmacokinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3780123/),[h·μg] / [ml],4.96,178593,DB01427,Amrinone
,3780123,AUC,"The AUC was higher for the slow acetylators, 4.96 micrograms X hr X ml-1, than for the fast acetylators, 2.20 micrograms X hr X ml-1 (P less than 0.01).",Effect of the acetylator phenotype on amrinone pharmacokinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3780123/),[h·μg] / [ml],2.20,178594,DB01427,Amrinone
,8450600,cardiac index,Mil increased the cardiac index significantly (p < 0.05) 4 h after administrations from 2.3 +/- 0.4 to 2.9 +/- 0.6 L/min/m2.,Hemodynamic effects of milrinone in patients with congestive heart failure--short- and long-term follow up studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8450600/),,2.3,184966,DB01427,Amrinone
,8450600,cardiac index,Mil increased the cardiac index significantly (p < 0.05) 4 h after administrations from 2.3 +/- 0.4 to 2.9 +/- 0.6 L/min/m2.,Hemodynamic effects of milrinone in patients with congestive heart failure--short- and long-term follow up studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8450600/),,2.9,184967,DB01427,Amrinone
,1741517,Protein binding,"Protein binding of amrinone, assayed by equilibrium dialysis, was 21.6 +/- 2.5%.",Pharmacokinetics of amrinone during cardiac surgery. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1741517/),%,21.6,188843,DB01427,Amrinone
,15747518,therapeutic plasma concentration,"After stopping infusion of milrinone, the plasma concentration of milrinone was 792.7 ng x ml(-1) (therapeutic plasma concentration: 100-200 ng x ml(-1)).",[A case of continuous infusion of milrinone during continuous venovenous hemofiltration causing high plasma concentration of milrinone]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15747518/),[ng] / [ml],100-200,192443,DB01427,Amrinone
,8797620,plasma,"In the double-blind, dose-finding study, dose-dependent inotropic/vasodilating hemodynamic effects were documented for percent changes in cardiac index (+21.2%, +25.8%, and +30.9%, respectively) and pulmonary artery occlusion pressure (-12.8%, -17.0%, -41.3%, respectively) vs. plasma drug concentration at the equilibrium state (6 hrs after starting continuous infusion; 97 +/- 13, 197 +/- 22, and 284 +/- 28 ng/mL, respectively).","Multicenter, double-blind study of intravenous milrinone for patients with acute heart failure in Japan. Japan Intravenous Milrinone Investigators. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8797620/),[ng] / [ml],97,201917,DB01427,Amrinone
,8797620,plasma,"In the double-blind, dose-finding study, dose-dependent inotropic/vasodilating hemodynamic effects were documented for percent changes in cardiac index (+21.2%, +25.8%, and +30.9%, respectively) and pulmonary artery occlusion pressure (-12.8%, -17.0%, -41.3%, respectively) vs. plasma drug concentration at the equilibrium state (6 hrs after starting continuous infusion; 97 +/- 13, 197 +/- 22, and 284 +/- 28 ng/mL, respectively).","Multicenter, double-blind study of intravenous milrinone for patients with acute heart failure in Japan. Japan Intravenous Milrinone Investigators. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8797620/),[ng] / [ml],197,201918,DB01427,Amrinone
,8797620,pulmonary artery occlusion pressure,"In the placebo-controlled, double-blind, comparative study, the milrinone group exhibited marked improvement in cardiovascular hemodynamics (pulmonary artery occlusion pressure: from 26 +/- 6 to 15 +/- 3 mm Hg; cardiac index: from 2.6 +/- 0.9 to 3.3 +/- 1.1 L/min/m2) within 15 mins after starting drug administration.","Multicenter, double-blind study of intravenous milrinone for patients with acute heart failure in Japan. Japan Intravenous Milrinone Investigators. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8797620/),,26,201919,DB01427,Amrinone
,8797620,pulmonary artery occlusion pressure,"In the placebo-controlled, double-blind, comparative study, the milrinone group exhibited marked improvement in cardiovascular hemodynamics (pulmonary artery occlusion pressure: from 26 +/- 6 to 15 +/- 3 mm Hg; cardiac index: from 2.6 +/- 0.9 to 3.3 +/- 1.1 L/min/m2) within 15 mins after starting drug administration.","Multicenter, double-blind study of intravenous milrinone for patients with acute heart failure in Japan. Japan Intravenous Milrinone Investigators. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8797620/),,15,201920,DB01427,Amrinone
,8797620,cardiac index,"In the placebo-controlled, double-blind, comparative study, the milrinone group exhibited marked improvement in cardiovascular hemodynamics (pulmonary artery occlusion pressure: from 26 +/- 6 to 15 +/- 3 mm Hg; cardiac index: from 2.6 +/- 0.9 to 3.3 +/- 1.1 L/min/m2) within 15 mins after starting drug administration.","Multicenter, double-blind study of intravenous milrinone for patients with acute heart failure in Japan. Japan Intravenous Milrinone Investigators. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8797620/),[l] / [m2·min],2.6,201921,DB01427,Amrinone
,8797620,cardiac index,"In the placebo-controlled, double-blind, comparative study, the milrinone group exhibited marked improvement in cardiovascular hemodynamics (pulmonary artery occlusion pressure: from 26 +/- 6 to 15 +/- 3 mm Hg; cardiac index: from 2.6 +/- 0.9 to 3.3 +/- 1.1 L/min/m2) within 15 mins after starting drug administration.","Multicenter, double-blind study of intravenous milrinone for patients with acute heart failure in Japan. Japan Intravenous Milrinone Investigators. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8797620/),[l] / [m2·min],3.3,201922,DB01427,Amrinone
,8031942,injection interval,The injection interval is 11 min.,Amrinone and N-acetylamrinone assay in human plasma using solid-phase extraction and reversed-phase chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8031942/),,11,212242,DB01427,Amrinone
,28099979,CL,The estimated value of CL is 7.65 mL/minute/3.4 kg (3.05 mL/minute/kg).,Milrinone Pharmacokinetics and Pharmacodynamics in Neonates with Persistent Pulmonary Hypertension of the Newborn. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28099979/),[ml] / [3.4·kg·min],7.65,214652,DB01427,Amrinone
,28099979,CL,The estimated value of CL is 7.65 mL/minute/3.4 kg (3.05 mL/minute/kg).,Milrinone Pharmacokinetics and Pharmacodynamics in Neonates with Persistent Pulmonary Hypertension of the Newborn. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28099979/),[ml] / [kg·min],3.05,214653,DB01427,Amrinone
,24690585,m/,The electrospray was operated in the negative ionization mode and monitored the following mass transitions: m/z 212.1 → 140.0 at 36 eV for milrinone and m/z 252.1 → 156.1 at 32 eV for olprinone.,A specific and sensitive HPLC-MS/MS micromethod for milrinone plasma levels determination after inhalation in cardiac patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24690585/),,212.1,220007,DB01427,Amrinone
,24690585,m/,The electrospray was operated in the negative ionization mode and monitored the following mass transitions: m/z 212.1 → 140.0 at 36 eV for milrinone and m/z 252.1 → 156.1 at 32 eV for olprinone.,A specific and sensitive HPLC-MS/MS micromethod for milrinone plasma levels determination after inhalation in cardiac patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24690585/),,140.0,220008,DB01427,Amrinone
,24690585,m/z,The electrospray was operated in the negative ionization mode and monitored the following mass transitions: m/z 212.1 → 140.0 at 36 eV for milrinone and m/z 252.1 → 156.1 at 32 eV for olprinone.,A specific and sensitive HPLC-MS/MS micromethod for milrinone plasma levels determination after inhalation in cardiac patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24690585/),,252.1,220009,DB01427,Amrinone
,24690585,m/z,The electrospray was operated in the negative ionization mode and monitored the following mass transitions: m/z 212.1 → 140.0 at 36 eV for milrinone and m/z 252.1 → 156.1 at 32 eV for olprinone.,A specific and sensitive HPLC-MS/MS micromethod for milrinone plasma levels determination after inhalation in cardiac patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24690585/),,156.1,220010,DB01427,Amrinone
≥,24690585,recovery,"Mean drug recovery and accuracy were ≥72.3% and 96.0%, respectively.",A specific and sensitive HPLC-MS/MS micromethod for milrinone plasma levels determination after inhalation in cardiac patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24690585/),%,72.3,220011,DB01427,Amrinone
,24690585,recovery,"Mean drug recovery and accuracy were ≥72.3% and 96.0%, respectively.",A specific and sensitive HPLC-MS/MS micromethod for milrinone plasma levels determination after inhalation in cardiac patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24690585/),,96,220012,DB01427,Amrinone
,16124923,Recovery,Recovery ranged from 52-69% over a 40-fold range of plasma concentrations from 50 to 2000 ng/mL.,A sensitive and specific high performance liquid chromatographic assay for milrinone in rat and human plasma using a commercially available internal standard and low sample volume. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16124923/),%,52-69,226811,DB01427,Amrinone
,25860636,clearance,Patients with AKI had significantly lower milrinone clearance (4.72 ± 2.26 L/h per 70 kg) compared with published data in patients without AKI.,Retrospective Evaluation of Milrinone Pharmacokinetics in Children With Kidney Injury. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25860636/),[l] / [70·h·kg],4.72,229743,DB01427,Amrinone
,25860636,clearance,There was large between-patient variability in milrinone clearance (range: 2.91-13.6 L/h per 70 kg).,Retrospective Evaluation of Milrinone Pharmacokinetics in Children With Kidney Injury. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25860636/),[l] / [70·h·kg],2.91-13.6,229744,DB01427,Amrinone
,25860636,Clearance,Clearance in patients on CRRT ranged from 2.8 to 7.19 L/h per 70 kg.,Retrospective Evaluation of Milrinone Pharmacokinetics in Children With Kidney Injury. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25860636/),[l] / [70·h·kg],2.8 to 7.19,229745,DB01427,Amrinone
,10972600,clearance,Amrinone clearance was 2.4 +/- 0.9 mL/kg/min in neonates and 3.2 +/- 1.2 mL/kg/min in infants (p < 0.05).,Pharmacokinetics of amrinone in neonates and infants. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10972600/),[ml] / [kg·min],2.4,233222,DB01427,Amrinone
,10972600,clearance,Amrinone clearance was 2.4 +/- 0.9 mL/kg/min in neonates and 3.2 +/- 1.2 mL/kg/min in infants (p < 0.05).,Pharmacokinetics of amrinone in neonates and infants. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10972600/),[ml] / [kg·min],3.2,233223,DB01427,Amrinone
,10972600,elimination half-life,The elimination half-life of amrinone was 10.7 +/- 6.7 hours in neonates and 6.1 +/- 1.4 hours in infants (p < 0.05).,Pharmacokinetics of amrinone in neonates and infants. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10972600/),h,10.7,233224,DB01427,Amrinone
,10972600,elimination half-life,The elimination half-life of amrinone was 10.7 +/- 6.7 hours in neonates and 6.1 +/- 1.4 hours in infants (p < 0.05).,Pharmacokinetics of amrinone in neonates and infants. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10972600/),h,6.1,233225,DB01427,Amrinone
,16551899,ultrafiltration drug clearance,All patients in this study demonstrated a modified ultrafiltration concentrating effect that occurred despite a modified ultrafiltration drug clearance of 3.3 mL x kg(-1) x min(-1).,Population pharmacokinetics of milrinone in neonates with hypoplastic left heart syndrome undergoing stage I reconstruction. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16551899/),[ml] / [kg·min],3.3,246800,DB01427,Amrinone
,16551899,clearance,"Postoperatively, milrinone clearance was significantly impaired (0.4 mL x kg(-1) x min(-1)), improved by the 12th postoperative hour, and approached steady-state clearance (2.6 mL x kg(-1) x min(-1)) by postoperative day 4.",Population pharmacokinetics of milrinone in neonates with hypoplastic left heart syndrome undergoing stage I reconstruction. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16551899/),[ml] / [kg·min],0.4,246801,DB01427,Amrinone
,16551899,steady-state clearance,"Postoperatively, milrinone clearance was significantly impaired (0.4 mL x kg(-1) x min(-1)), improved by the 12th postoperative hour, and approached steady-state clearance (2.6 mL x kg(-1) x min(-1)) by postoperative day 4.",Population pharmacokinetics of milrinone in neonates with hypoplastic left heart syndrome undergoing stage I reconstruction. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16551899/),[ml] / [kg·min],2.6,246802,DB01427,Amrinone
,16551899,infusion rate,"In the postoperative setting of markedly impaired renal function, an infusion rate of 0.2 microg x kg(-1) x min(-1) should be considered.",Population pharmacokinetics of milrinone in neonates with hypoplastic left heart syndrome undergoing stage I reconstruction. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16551899/),[μg] / [kg·min],0.2,246803,DB01427,Amrinone
,6886991,bioavailability,"The mean (+/-SD) bioavailability, based on the area under the plasma concentration versus time curves, was 0.93 +/- 0.12.",Oral bioavailability and intravenous pharmacokinetics of amrinone in humans. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6886991/),,0.93,259792,DB01427,Amrinone
,6886991,"apparent first-order terminal elimination rate constant, beta,","The plasma data for these subjects during the intravenous phase was described by an open two-compartment body model with a mean (+/-SD) apparent first-order terminal elimination rate constant, beta, of 0.19 +/- 0.06 hr-1, which corresponds to a half-life of 3.6 hr.",Oral bioavailability and intravenous pharmacokinetics of amrinone in humans. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6886991/),1/[h],0.19,259793,DB01427,Amrinone
,6886991,half-life,"The plasma data for these subjects during the intravenous phase was described by an open two-compartment body model with a mean (+/-SD) apparent first-order terminal elimination rate constant, beta, of 0.19 +/- 0.06 hr-1, which corresponds to a half-life of 3.6 hr.",Oral bioavailability and intravenous pharmacokinetics of amrinone in humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6886991/),h,3.6,259794,DB01427,Amrinone
,16690639,clearance,"Milrinone pharmacokinetics were described using a one-compartment model with first-order elimination rate, with a population mean clearance (CV%) of 35 ml/h (24%) and volume of distribution of 512 ml (21%) and estimated half-life of 10 h.",Population pharmacokinetics and dosing regimen design of milrinone in preterm infants. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16690639/),[ml] / [h],35,263271,DB01427,Amrinone
,16690639,volume of distribution,"Milrinone pharmacokinetics were described using a one-compartment model with first-order elimination rate, with a population mean clearance (CV%) of 35 ml/h (24%) and volume of distribution of 512 ml (21%) and estimated half-life of 10 h.",Population pharmacokinetics and dosing regimen design of milrinone in preterm infants. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16690639/),ml,512,263272,DB01427,Amrinone
,16690639,half-life,"Milrinone pharmacokinetics were described using a one-compartment model with first-order elimination rate, with a population mean clearance (CV%) of 35 ml/h (24%) and volume of distribution of 512 ml (21%) and estimated half-life of 10 h.",Population pharmacokinetics and dosing regimen design of milrinone in preterm infants. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16690639/),h,10,263273,DB01427,Amrinone
,31317556,steady-state therapeutic concentrations,We performed dose-exposure simulations targeting steady-state therapeutic concentrations of 100-300 ng/mL previously established in adults and children with cardiac dysfunction.,"Population Pharmacokinetics of Milrinone in Infants, Children, and Adolescents. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31317556/),[ng] / [ml],100-300,268373,DB01427,Amrinone
,9459233,Steady-state plasma levels,"Steady-state plasma levels in the small and large dose groups were within the adult therapeutic range (113 +/- 39 and 206 +/- 74 ng/mL, respectively).",Pharmacokinetics and side effects of milrinone in infants and children after open heart surgery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9459233/),[ng] / [ml],113,272964,DB01427,Amrinone
,9459233,Steady-state plasma levels,"Steady-state plasma levels in the small and large dose groups were within the adult therapeutic range (113 +/- 39 and 206 +/- 74 ng/mL, respectively).",Pharmacokinetics and side effects of milrinone in infants and children after open heart surgery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9459233/),[ng] / [ml],206,272965,DB01427,Amrinone
,9459233,volumes of distribution (Vbeta),"The volumes of distribution (Vbeta) in infants (0.9 L/kg) and children (0.7 L/kg) were not different, but infants had significantly lower milrinone clearance (3.8 vs 5.9 mL x kg(-1) x min(-1)).",Pharmacokinetics and side effects of milrinone in infants and children after open heart surgery. ,Vb-Q62,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9459233/),[l] / [kg],0.9,272966,DB01427,Amrinone
,9459233,volumes of distribution (Vbeta),"The volumes of distribution (Vbeta) in infants (0.9 L/kg) and children (0.7 L/kg) were not different, but infants had significantly lower milrinone clearance (3.8 vs 5.9 mL x kg(-1) x min(-1)).",Pharmacokinetics and side effects of milrinone in infants and children after open heart surgery. ,Vb-Q62,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9459233/),[l] / [kg],0.7,272967,DB01427,Amrinone
,9459233,clearance,"The volumes of distribution (Vbeta) in infants (0.9 L/kg) and children (0.7 L/kg) were not different, but infants had significantly lower milrinone clearance (3.8 vs 5.9 mL x kg(-1) x min(-1)).",Pharmacokinetics and side effects of milrinone in infants and children after open heart surgery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9459233/),[ml] / [kg·min],3.8,272968,DB01427,Amrinone
,9459233,clearance,"The volumes of distribution (Vbeta) in infants (0.9 L/kg) and children (0.7 L/kg) were not different, but infants had significantly lower milrinone clearance (3.8 vs 5.9 mL x kg(-1) x min(-1)).",Pharmacokinetics and side effects of milrinone in infants and children after open heart surgery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9459233/),[ml] / [kg·min],5.9,272969,DB01427,Amrinone
